Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M SwainR A Gams

Abstract

To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer. Between November 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicenter, double-blind studies (088001 and 088006). Patients received fluorouracil, doxorubicin, and cyclophosphamide (FAC) with either DZR (DZR-to-doxorubicin ratio, 10:1) or placebo (PLA) every 3 weeks and were monitored with serial multiplegated acquisition (MUGA) scans. The hazards ratio (HR) of PLA to DZR for a cardiac event, which was predefined ejection fraction changes or congestive heart failure (CHF), was 2.63 (95% confidence interval [CI], 1.61 to 4.27; P < .001) for 088001 and 2.00 (95% CI, 1.01 to 3.96; P = .038) for 088006. The objective response rates for 088001 were 46.8% for DZR and 60.5% for PLA, a difference of 14% (95% CI, -25% to -2%; P = .019), and for 088006 were 53.7% for DZR and 49.3% for PLA, a difference of 4% (95% CI, -13% to 22%; P = .63). Time to progression and survival were not significantly different between treatment arms in either study. Toxicities on the DZR arms included lower granulocyte and platelet counts at nadir (P = .009 and P = .004, respectivel...Continue Reading

Citations

Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoM J Egorin
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroG N Hortobagyi
Nov 23, 2000·Cancer Control : Journal of the Moffitt Cancer Center·S M Lichtman, G Villani
May 30, 2002·European Journal of Heart Failure·M I Gharib, A K Burnett
Aug 31, 2002·Medical and Pediatric Oncology·P A Voûte
Nov 28, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claudia LangebrakeJörg Ritter
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O HequetB Coiffier
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·George Youssef, Matthew Links
Feb 15, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Laura Boehnke MichaudJanet Espirito
Sep 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Martin SterbaVladimír Gersl
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph R CarverUNKNOWN ASCO Cancer Survivorship Expert Panel
Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robin L Jones
Aug 19, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Manabu MinamiHisanori Horiuchi
Sep 16, 2010·Nature Reviews. Cardiology·Michael S Ewer, Steven M Ewer
Jun 4, 2011·Expert Opinion on Drug Safety·Pierantonio MennaGiorgio Minotti
Jan 3, 2014·The Journal of Clinical Investigation·Yoshihiko IchikawaHossein Ardehali
Apr 29, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John Greene, Bryan Hennessy
Oct 23, 2015·Oxidative Medicine and Cellular Longevity·Paweorn AngsutararuxSurapol Issaragrisil
Oct 16, 2015·Nature Reviews. Clinical Oncology·Sherry-Ann BrownJoerg Herrmann
Mar 18, 2016·The Oncologist·Michael S Ewer, Sandra M Swain
Nov 11, 2016·Circulation·Biykem BozkurtUNKNOWN American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on
Oct 19, 2016·Journal of Cardiovascular Medicine·Christian CadedduGiuseppe Mercuro
Oct 19, 2016·Journal of Cardiovascular Medicine·Pier P BassareoGiuseppe Mercuro
Sep 16, 2017·Therapeutic Advances in Cardiovascular Disease·Nicole S KleeR Clinton Webb
Jun 7, 2018·NPJ Precision Oncology·Xinqiang HanWendi Liu
Jul 11, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Michael P CatanzaroQiangrong Liang
May 15, 2019·Current Opinion in Cardiology·Abdulrazzak ZarifaJuan Lopez-Mattei
Sep 11, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Meredith K MortMichael K Keng
Apr 1, 2020·Frontiers in Cardiovascular Medicine·Alessandra MurabitoAlessandra Ghigo
Mar 3, 1999·European Journal of Haematology·T NousiainenJ Hartikainen
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Hellmann
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoW C Wood

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.